Public Accounts Committee chairman Sean Fleming intends to probe the recent drug pricing deal amid concerns around the purported savings attached to the agreement.
Fleming said he was troubled by the major variation in the savings claimed by the only two parties to the multibillion euro deal that was announced last month.
“There is obviously a huge difference,” Fleming said.
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Get a Business Account for you and your team